Bioblast Pharma Ltd. regained compliance with a Nasdaq listing rule that requires the company to maintain a minimum bid price of $1 per share.
After 10 consecutive business days following the company's 1-for-5 reverse stock split on Sept. 25, the closing bid price for Bioblast's ordinary shares was $1 per share or greater, the company said in a filing.